Cargando…

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia

To determine the potential benefits and feasibility of administering maintenance therapy with dinutuximab beta for high-risk neuroblastoma (HRNB) in clinical practice, a retrospective review of charts of patients with HRNB treated at a single center in Croatia (2012–2021) was undertaken. Of 23 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Giljević, Jasminka Stepan, Rajačić, Nada, Mikulić, Danko, Batoš, Ana Tripalo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318789/
https://www.ncbi.nlm.nih.gov/pubmed/35883927
http://dx.doi.org/10.3390/children9070943
_version_ 1784755379969720320
author Giljević, Jasminka Stepan
Rajačić, Nada
Mikulić, Danko
Batoš, Ana Tripalo
author_facet Giljević, Jasminka Stepan
Rajačić, Nada
Mikulić, Danko
Batoš, Ana Tripalo
author_sort Giljević, Jasminka Stepan
collection PubMed
description To determine the potential benefits and feasibility of administering maintenance therapy with dinutuximab beta for high-risk neuroblastoma (HRNB) in clinical practice, a retrospective review of charts of patients with HRNB treated at a single center in Croatia (2012–2021) was undertaken. Of 23 patients with HRNB, 11 received up to five cycles of dinutuximab beta as part of multimodal therapy; 12 patients did not (i.e., no immunotherapy). In the no immunotherapy group, one patient had complete remission (8%), and 11 patients died of tumor progression (92%). In the dinutuximab beta group, eight patients had complete remission (73%; median duration of response 5 years and 2 months), one had stable disease (9%), and two died of disease (18%). Patients who received dinutuximab beta had a higher median event-free survival (40.0 months [range: 12.5–83.0]) and median overall survival (56.0 months [range: 16.2–101.0]) than those who did not (12.9 months [range: 3.3–126.0] and 20.7 months [3.3–126.0], respectively). Dinutuximab beta was generally well tolerated; adverse events were manageable and as reported in clinical studies. These results confirm the benefits and feasibility of maintenance therapy with dinutuximab beta as part of multimodal therapy for patients with HRNB in real-world clinical practice.
format Online
Article
Text
id pubmed-9318789
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93187892022-07-27 Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia Giljević, Jasminka Stepan Rajačić, Nada Mikulić, Danko Batoš, Ana Tripalo Children (Basel) Article To determine the potential benefits and feasibility of administering maintenance therapy with dinutuximab beta for high-risk neuroblastoma (HRNB) in clinical practice, a retrospective review of charts of patients with HRNB treated at a single center in Croatia (2012–2021) was undertaken. Of 23 patients with HRNB, 11 received up to five cycles of dinutuximab beta as part of multimodal therapy; 12 patients did not (i.e., no immunotherapy). In the no immunotherapy group, one patient had complete remission (8%), and 11 patients died of tumor progression (92%). In the dinutuximab beta group, eight patients had complete remission (73%; median duration of response 5 years and 2 months), one had stable disease (9%), and two died of disease (18%). Patients who received dinutuximab beta had a higher median event-free survival (40.0 months [range: 12.5–83.0]) and median overall survival (56.0 months [range: 16.2–101.0]) than those who did not (12.9 months [range: 3.3–126.0] and 20.7 months [3.3–126.0], respectively). Dinutuximab beta was generally well tolerated; adverse events were manageable and as reported in clinical studies. These results confirm the benefits and feasibility of maintenance therapy with dinutuximab beta as part of multimodal therapy for patients with HRNB in real-world clinical practice. MDPI 2022-06-23 /pmc/articles/PMC9318789/ /pubmed/35883927 http://dx.doi.org/10.3390/children9070943 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Giljević, Jasminka Stepan
Rajačić, Nada
Mikulić, Danko
Batoš, Ana Tripalo
Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
title Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
title_full Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
title_fullStr Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
title_full_unstemmed Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
title_short Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
title_sort dinutuximab beta in children with high-risk neuroblastoma: experience from a single center in croatia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318789/
https://www.ncbi.nlm.nih.gov/pubmed/35883927
http://dx.doi.org/10.3390/children9070943
work_keys_str_mv AT giljevicjasminkastepan dinutuximabbetainchildrenwithhighriskneuroblastomaexperiencefromasinglecenterincroatia
AT rajacicnada dinutuximabbetainchildrenwithhighriskneuroblastomaexperiencefromasinglecenterincroatia
AT mikulicdanko dinutuximabbetainchildrenwithhighriskneuroblastomaexperiencefromasinglecenterincroatia
AT batosanatripalo dinutuximabbetainchildrenwithhighriskneuroblastomaexperiencefromasinglecenterincroatia